KLRK1 and prostate cancer: Therefore, we suppose that NKG2D-CAR T cells expressing IL-7 would have the capacity to persist in the immuno-suppressive microenvironment in prostate cancer tissues and induce potent antitumor immunity in patients, but more evidence is needed.